-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

619.P1.28 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I

Symposia: Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 7, 2024: 5:30 PM-7:30 PM
Halls G-H (San Diego Convention Center)

Adam Sciambi, PhD1*, Daniel Mendoza, PhD1*, Kathryn Thompson1*, Lan W. Beppu2*, Benjamin Geller, MSc3*, Indira Krishnan, PhD1*, Lubna Nousheen, M.S.4*, Shu Wang, PhD1*, Charlie Murphy, PhD4*, Jerald P. Radich, MD5 and Todd E. Druley, MD, PhD6

1Mission Bio, South San Francisco, CA
2Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
3R&D, Mission Bio, South San Francisco, CA
4Mission Bio, SOUTH SAN FRANCISCO, CA
5Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA
6Mission Bio, Inc, South San Francisco, CA

Sze Pui Tsui, MSc1,2*, Ho-Wan Ip1*, Stephen Lam, PhD, MBBS,2*, Chi Yeung Fung2*, Wing-Hei Lai2*, Edmond Shiu-Kwan Ma, MD3, Jocelyn P.Y. Sim2* and Anskar Y.H. Leung, MD, PhD2,4

1Department of Pathology, Queen Mary Hospital, Hong Kong, China
2Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
3Department of Pathology, Hong Kong Sanitorium & Hospital, Hong Kong, China
4Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong, China

Swe Mar Linn, MD1, Nihar Desai, MBBS, MD, DM1*, Steven M. Chan, MD, PhD1,2, Andre C. Schuh, MD, FRCPC1,2, Aniket Banker, MD1,2*, Marta Beata Davidson, MD, PhD1, Guillaume Richard-Carpentier, MD, FRCPC1, Aron Shimmer, MD, PhD, FRCPC1*, Dawn C. Maze, MD, FRCPC, MSc1,2, Karen Yee, MD, FRCPC1*, Mark D. Minden, MD, PhD1*, Vikas Gupta, MD, FRCP, FRCPath1,2, Tracy Stockley, PhD2*, Hassan Sibai, MD1, Jose-Mario Capo-Chichi, PhD2,3,4*, Anne Maria Tierens, MD, PhD2,3,4 and Dennis Dong Hwan Kim, MD, PhD1,2,3

1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
2University of Toronto, Toronto, Canada
3Measurable residual disease working group, Princess Margaret Cancer Centre, Toronto, ON, Canada
4Laboratory Medicine Program, Toronto General Hospital, University Health Network, Toronto, Canada

Rula Gladden, MD1, Everett Fan2*, Shruti Bhise3*, Rhonda E. Ries, MA4*, Rachel Ferina3*, Sami B. Kanaan5*, Mark A Mendoza6*, Jobelle Peralta3*, Rachel Gate, PhD7*, Soheil Meshinchi, MD, PhD4 and Scott N Furlan, MD4,8*

1Fred Hutch Cancer Center, Seattle, WA
2Fred Hutch Cancer Center, Seattle
3Fred Hutchinson Cancer Center, Seattle, WA
4Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA
5Fred Hutchinson Cancer Research Center, Seattle, WA
6FRED HUTCHINSON CANCER RESEARCH CENTER, Seattle
710X Genomics, Pleasanton, CA
8Department of Pediatrics, University of Washington, Mill Creek, WA

Wei-Ying Jen, MD, FRCPath, MA1*, Koji Sasaki, MD1, Farhad Ravandi, MBBS2, Tapan M. Kadia, MD1, Sa A. Wang, MD3, Wei Wang, MD, PhD4*, Sanam Loghavi, MD3, Naval Daver, MD5, Courtney D. DiNardo, MD, MSc6, Ghayas C. Issa, MD1, Hussein A. Abbas, MD, PhD1, Cedric Nasnas, MD1*, Alex Bataller, MD, PhD1*, Samuel Urrutia, MD7, Sherry Pierce, BSN, BA1*, Hagop M. Kantarjian, MD1 and Nicholas J. Short, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX
5MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
7Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Manna Ahmed, MD1,2*, Dharmendra Kashyap, PhD1,2*, Christopher Miranda1,2*, Hannah Kim3*, Martin P Carroll, MD4, Peter Abdelmessieh, MD1* and Cihangir Duy, PhD1,2

1Fox Chase Cancer Center, Philadelphia, PA
2Cancer Epigenetics Institute, Philadelphia, PA
3Temple University, Philadelphia
4Division of Hematology/Oncology, Department of Medicine, The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA

Paola Minetto, MD1, Fabio Guolo, MD, PhD1,2, Sara Rosellini3*, Alfonso Piciocchi4*, Giovanni Marconi, MD5, Ernesta Audisio, MD6*, Giorgio Priolo7*, Cristina Papayannidis, MD, PhD8, Maurizio Martelli, MD9*, Giovanni Marsili4*, Monica Bocchia, MD10*, Francesco Lanza, MD11*, Albana Lico12*, Fabio Ciceri, MD13*, Matteo Giovanni Della Porta, MD14*, Marco Frigeni15*, Luisa Giaccone, MD, PhD16*, Germana Beltrami, MD17*, Erika Borlenghi, MD18*, Maria Chiara Di Chio19*, Carmine Selleri, MD20, Enrico Crea, PharmD4*, Irene Urbino21*, Chiara Sartor, MD22*, Clara Minotti23*, Valentina Arena4*, Jacopo Nanni, MD22*, Giorgia Simonetti, Ph.D.24*, Maria Teresa Bochicchio25*, Giuseppe Saglio, MD26, Adriano Venditti27, Marco Vignetti, MD4*, Paola Fazi28*, Elisabetta Tedone1*, Giovanni Martinelli, M.D.29 and Roberto Massimo Lemoli, MD30,31*

1IRCCS Ospedale Policlinico San Martino, Genoa, Italy
2Hematology Unit, Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
3Servizio di Citofluorimetria, Dipartimento di Anatomia Patologica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
4GIMEMA Foundation, Rome, Italy
5Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Meldola, Italy
6SC EMATOLOGIA 2, AOU CITTA DELLA SALUTE E DELLA SCIENZA, OSPEDALE S. GIOVANNI BATTISTA MOLINETTE, Torino, ITA
7Haematology 2 - A.O.U San Giovanni Battista, Turin, ITA
8IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
9Hematology Section, Department of Traslational and Precision Medicine, Sapienza University of Rome, Roma, Italy
10Hematology, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy
11Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy
12Hematology Unit, Hematology Unit, San Bortolo Hospital, Vicenza, Italy, Vicenza, Italy
13Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. San Raffaele Scientific Institute, Milan, Italy
14IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
15Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
16Univesity of Torino, AOU Città Della Salute E Della Scienza Di Torino,, Torino, ITA
17U.O. Ematologia e terapie cellulari, IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy
18Hematology, ASST Spedali Civili, Brescia, Italy
19Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
20Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Salerno, Italy
21Department of Oncology and Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy
22Department of Medical and Surgical Sciences - University of Bologna, Bologna, Italy
23Department of Translational and Precision Medicine, Division of Hematology, Sapienza University, Rome, Italy
24IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy
25IRCSS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l, Meldola, Italy
26Dept. of Clinical and Biological Sciences, University of Turin, Turin, Italy
27Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy
28GIMEMA Foundation, Data Center and Health Outcomes Research Unit, Rome, Italy
29IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy
30Clinic of Hematology, Department of Internal medicine (DiMI), University of Genoa, Genoa, Italy
31Clinica Ematologica, Dipartimento di Oncologia e Ematologia, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

Ping Wu, M.D., Ph.D.1*, Wei Ling, M.D.1*, Chengwei Luo Luo, M.D.1*, Lisi Huang, M.D.1*, Ruohao Xu, Ph.D.1*, Xiaoling Liang1*, Jiaqi Tan, M.D.1*, Jinghua Wang, M.D.1*, Peilong Lai, M.D., Ph.D.1*, Suijing Wu, M.D.1*, Birong Li1*, Haijie Huang1*, Suxia Geng, M.D., Ph.D.1*, Xin Du, PhD2 and Jianyu Weng, M.D., Ph.D.1*

1Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
2Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, WA, China

Gail J. Roboz, MD1, Nuria Mencia-Trinchant, PhD2*, Gabriela Pereira3*, Ellen K. Ritchie, MD4, Justin D. Kaner, MD5, Michael Samuel4*, Michal Bar-Natan, MD4, Jonathan Canaani, MD6, Sharmaine Griffith-Baker7*, Pinkal Desai8 and Monica L Guzman, PhD4

1Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY
2Hematology & Medical Oncology, New York, NY
3Weill Cornell Medicine, NewYork-Presbyterian, Meyer Cancer Cente, New York
4Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, New York, NY
5Leukemia Program, New York-Presbyterian/Weill, Syosset, NY
6Weill Cornell Medicine and The New York Presbyterian Hospital in New York City, Brooklyn, NY
7Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
8Weill Cornell Medicine New York Presbyterian Hospital, New York, NY

*signifies non-member of ASH